Ipsen takes on another ADC, this time from a China-based biotech
Ipsen is adding a second antibody-drug conjugate to its plate.
The French drugmaker said Thursday that it has inked a global licensing agreement for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
